No Data
[Brokerage Focus] China International: In January, Global and China Medical financing showed signs of recovery, focusing on recommending companies with good annual report expectations.
Jinwu Finance | According to the renowned Medical database Artery Network Statistics, the total disclosed financing amount for the Global Medical Health Industry in January 2025 was 8.004 billion USD, an increase of 100.5% month-on-month from December. The disclosed financing amount for China's Medical Health Industry in January was 0.956 billion USD, increasing by 90.8% and 71.3% compared to November and December, respectively. After a significant decline in the total financing amount for the Global Medical Health Industry in 2022-23, there was a year-on-year rebound of 1.4% in 2024, indicating that January is part of a sustained recovery. The total financing amount for China's Medical Health Industry after 2022.
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Luye Pharma Group's (HKG:2186) Earnings Have Declined Over Five Years, Contributing to Shareholders 55% Loss
LUYE PHARMA is a low-value buy.
Hong Kong stocks experienced brief fluctuations due to external influences, and LUYE PHARMA (2186.HK) is less than ten percent away from its temporary 52-week low of 1.97 yuan (recorded on February 3 this year). Additionally, it has been at low levels since December 2022, which is over two years and two months ago, indicating strong defensiveness. The group is committed to developing, producing, promoting, and selling Innovative Drugs in the four largest and fastest-growing therapeutic areas globally, namely oncology, central nervous system, cardiovascular system, and digestive and metabolic fields in China, the USA, Europe, and Other countries or regions. The announcement regarding the fiscal year 2024 was released after the market closed on September 29 last year.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
